News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Jul 27, 2016
London, UK; 27 June 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing
Jul 18, 2016
LONDON, UK, 18 July 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeut
Jul 12, 2016
London, UK, 12 July 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeut
Jun 27, 2016
- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures
Jun 21, 2016
- Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS –
May 31, 2016
London, UK, 31 May 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeuti
May 16, 2016
London, UK, 16 May 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeuti
May 05, 2016
- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome –
May 04, 2016
London, UK, 4 May 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutic
Apr 28, 2016
London, UK, 28 Apr 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeuti

Pages